CONNIE A. SIZEMORE, PharmD

Published Clinical Pharmacy Specialist leader with more than twenty years of hematologic, immunotherapy and stem cell transplantation experience. Scientifically trained professional with strong clinical, cellular therapy background with excellent communication and collaboration skills. Responsible for identifying, developing, and managing relationships with current and future hematology/oncology thought leaders and other health care providers in academic and community practices. Results-driven Medical Scientist Liaison with high emotional intelligence and talent to engage in professional relationship building and networking. Thrives on taking on new opportunities and meeting tough challenges. Possesses valued analytical, communication and presentation skills.

2022-present: Inctye Ingenuity Awards- Chronic GVHD Judging Panel

2019- present: Sub-Acute Hematology Developmental Service Team

2013-present: Co-Chair Computerized Physician Order Entry Task Force: BMT Unit

2013-present: Co-Chair quarterly BMT/Leukemia/Immunotherapy Program Physician Newsletter

2013-present: Foundation for the Accreditation of Cellular Therapy (FACT) Clinical Subcommittee

2010-2014 - National Marrow Donor Program System (NMDP) Capacity Initiative

2009-present: Radiation Injury Treatment Network Committee

2006-present: BMT/Leukemia Medication Prevention Oversight Committee

2006-2010: Co-Chair Pharmacy Oncology Sub-Committee

2005-present: Pharmacy Management Team

2005-present: NSH Program BMT Quality Initiative

• "Going Beyond Day 180 Post Allogeneic Transplant with Chronic Graft Versus Host Disease” Presented at the nbmtLINK webinar- October 27, 2021
• "Biosimilars in Oncology Practice: Practical Strategies for Oncology Clinicians” Presented at the Advanced Practice Providers Oncology Summit – Atlanta Ga May 13, 2021 (0.1 CEU)
• “Surviving Transplant- Long Term Follow-Up” Presented at the Georgia Blood Cancer Conference 2019 Leukemia Lymphoma Society- Atlanta Ga, September 7, 2019
• “Chimeric Antigen Receptor Part 2” Presented at the 8th Annual Northside Hospital Oncology Nursing Symposium –Atlanta Ga, February 16, 2019
• “Chronic Graft Versus Host Disease Treatment” Presented at the National Cigna Medical Director Conference- Pittsburg PA April 20, 2018
• Understanding Chimeric Antigen Receptor T-Cell Therapy: Current Understanding and Management of Cytokine Release Syndrome” Presented at the 7th Annual Northside Hospital Oncology Nursing Symposium- Atlanta Ga, February 17, 2018 (0.1 CEU)
• “Long-Term Care Follow-up Post Hematopoietic Stem Cell Transplantation” Presented at 5th Annual Northside Hospital Oncology Nursing Symposium- Atlanta Ga, May 19, 2012 (0.1 CEU)
• Sizemore C, LaPorte J, Sanacore M, Holland H, Mccollum J, Westerman, J, Morris L, Bashey A, and Solomon, S. A Comparison of Toxicity and Mobilization Efficacy Following Two Different Doses of Cyclophosphamide for Mobilization Of Hematopoietic Stem Cells In Multiple Myeloma Patients. ASBMT Tandem Meeting – Abstract # 97-Oral Presentation, February 2011.
• Comparison of Toxicity and Mobilization Efficacy Following Two Different Doses of Cyclophosphamide for Mobilization of Hematopoietic Stem Cells in Multiple Myeloma Patients - ASBMT National Meeting Orlando Florida 2010
• “Educational Blitz: Antifungal, Antidepressant Therapy, Electrolyte Replacement, Pneumonia Treatment” Presented to Nurses and BMT Physicians at BMT of Georgia, Northside Hospital, Atlanta Georgia August 2006. Continuing Education Program (0.2CEU)

• Kronemberg O, Miller J, Sizemore C, Hanik M, Brown S, Bashey A, Solomon S, Morris LE, Holland HK, Solh M. A Prospective Pilot Study of Implementing a Sepsis Management Protocol among Adult Hematopoietic Stem Cell Transplant Recipients. ASBMT Tandem Meeting ABSTRACT # 564- Poster Presentation 2018
• Solomon S, Sizemore C, Sanacore M, Zhang X, Solh, M, Holland H, Morris L, Bashey A. Rituximab-Based First Line Treatment for Chronic GVHD Following Allogeneic Transplant: Single Center Analysis of 75 Patients. ASBMT Tandem Meeting Abstract #225- Poster Presentation 2018
• Solomon, S, Holland, K, Morris, L, Bashey, A, Sizemore C, Zhang, X, Brown, S, Connor, K. TBI-Based Myeloablative Haploidentical Stem Cell Transplantation is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors. 56th Annual ASH Meeting. Abstract# 426 –Oral Presentation December 2014.
• Sizemore, C, Morris, L., Holland,K., Bashey,A., Ridgeway, M., Zhang, X., Brown, S., Solomon,S. Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation. 56th Annual ASH Meeting. Abstract # 2487- Poster Presentation December 2014.
• Sizemore C, Bashey A, Morris L, Solomon S, Holland H. Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome. ASBMT Tandem Meeting. Abstract 397- Poster Presentation, February 2013
• Sanacore, M, Bashey, A, Sizemore.C, Holland H, Morris, L. Calcineurin Inhibitor-Free GVHD Prophylaxis with PostTransplant Cyclophosphamide and Brief-Course Sirolimus Results in Low Rates of Non-Relapse Mortality and Chronic GVHD Following Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (PBSCT). 55th Annual ASH Meeting. Poster and Oral Presentation, December 2013.
• Solomon S, Jacobson S, Sanacore M, Zhang X, Sizemore C, Brown S, Holland K, Morris L, Bashey A. Myeloablative Conditioning With PBSC Grafts For T-Replete Haploidentical Donor Hematopoietic Cell Transplantation Using Post Transplant Cyclophosphamide Results In Universal Engraftment, Low Rates Of GvHD, NRM and Excellent Survival Outcomes: An Analysis Of Two Consecutive Phase II Studies From a Single Center. 55th Annual ASH Meeting. Abstract # 60544 - Poster Presentation December 2013.
• Amaani Hussain, Sizemore C, Zhang, X, Sanacore M, Brown S, Morris L, Holland H, Solomon S. Bashey A. Lineage– Specific Chimerism and Incidence of Graft-Failure Following T-Cell Replete Haploidentical Transplantation Using Post Transplant Cyclophosphamide in Eighty-Nine Consecutive Patients From a Single-Center. 54th Annual ASH Meeting. Abstract# 3030- Poster Presentation, December 2012.
• Sizemore C, LaPorte J., Sanacore M, Holland H, Mccollum J, Westerman J, Morris L, Bashey A and Solomon S. A Comparison of Toxicity and Mobilization Efficacy Following Two Different Doses of Cyclophosphamide for Mobilization of Hematopoietic Stem Cells in Non-Hodgkin's Lymphoma Patients. ASBMT Tandem Meeting. Abstract #130- Poster, February 2011.
• Sizemore C, Bashey A, Manion K, Holland H, Morris L, Brown S, Zhang X and Solomon S. Total Outpatient Care for Myeloablative Unrelated Donor Hematopoietic Cell Transplantation: A Safe and Effective Alternative to Standard In-Patient Care. 52th Annual ASH Annual Meeting. Abstract #3525 - Poster, December 2011.
• Bashey A, Sizemore C, Manion K, Holland H, Solomon S, Brown S, Zhang X and Morris, L. T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide Results in Equivalent Nonrelapse Mortality and Disease-Free Survival Compared to Transplantation From HLA-Identical Sibling and Matched Unrelated Donors: A Stratified Cox Model Analysis of Two Hundred and Sixty Contemporaneous Allogeneic Transplants From a Single Center. 53th Annual ASH Annual Meeting. Abstract #833 – Oral Presentation, December 2011.
• Sizemore C, Bashey A, Manion K, Holland H, Morris L, Brown S, Zhang X, Solomon S. Low Dose Subcutaneous Alemtuzumab and Preemptive Donor Lymphocyte Infusion without Withdrawal of Immunosuppression Results in Low Non-Relapse Mortality Decreased Hospitalization, and Favorable Outcomes for High Risk Older Recipients of Unrelated Donor Allogeneic Transplants: A Prospective Phase II Trial. 53th Annual ASH Annual Meeting. Abstract #40374 - Poster, December 2011.
• Bashey A, Manion K, Morris L, Holland H, Connaghan G, Matthews R, Dooley A, Sizemore C, Kerns L, and Solomon S. Outpatient Management of both Myeloablative and Reduced-Intensity Allogeneic HCT Results in Low Non-Relapse Mortality Irrespective of HCT-CI. 49th ASH Annual Meeting. Abstracts #1505 – Poster, December 2007.

• Solomon S, Sizemore C, Morris, L., Holland,K., Ridgeway, M., Zhang, X., Brown, S, Bashey A.: Study Demonstrates Efficacy of Rituximab-Based First-Line cGVHD Therapy. Bone Marrow Transplantation 54(8):1218-1226, 2018.
• Solomon SR, Sizemore C, Zhang X, Brown S, Holland HK, Morris LE, Solh M, Bashey A.: Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. Biology of Blood and Marrow Transplantation, October, Vol. 22, Issue 10, pages 1816–1822, 2016.
• Solomon S, Sizemore C, Morris, L., Holland,K., Ridgeway, M., Zhang, X., Brown, S, Bashey A.: Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation. Biology of Blood and Marrow Transplantation 21(9):1576-82, 2015.
• Solomon S, Sizemore C, Sanacore M, Zhang X, Brown S, Holland H, Morris LE, Bashey A.: Total Body Irradiation Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors. Biology of Blood Marrow Transplant 21(7):1299-307, 2015.
• Solomon. S., Sizemore C, Zhang X, Brown S, Holland K, Morris L, Bashey A.: Preemptive DLI Without Withdrawal of Immunosuppressants to Promote Complete Donor T-Cell Chimerism Results in Favorable Outcomes for High Risk Older Recipients of Alemtuzumab Containing Reduced Intensity Unrelated Donor Allogeneic Transplant: A Prospective Phase II Trial. Bone Marrow Transplantation 32(18):1919-1926, 2014.
• Bashey A, Zhang X, Sizemore C, Brown S, Holland H, Morris L, and Solomon S.: T-Cell Replete HLA-Haploidentical hematopoietic Transplantation for Hematologic Malignancies Using PostTransplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation. Journal of Clinical Oncology 31:1310-1316, 2013
• Solomon S, Sizemore C, Sanacore M, Manion K, Holland K, Morris L, Brown S, Zhang X and Bashey A.: HaploIdentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial. Biology of Blood Marrow Transplant 18(12):1859-1866, 2012.